...
首页> 外文期刊>European journal of heart failure: journal of the Working Group on Heart Failure of the European Society of Cardiology >Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure.
【24h】

Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure.

机译:中部地区肾上腺髓质素作为慢性心力衰竭患者死亡率的新型预测指标。

获取原文
获取原文并翻译 | 示例
           

摘要

AIMS: Adrenomedullin (ADM) is a vasodilatory peptide. Its plasma levels or its precursors have not been evaluated in large populations of patients with chronic heart failure (CHF). We sought to explore mid-regional proADM (MR-proADM). METHODS AND RESULTS: We assessed MR-proADM in 501 CHF patients [age 63 +/- 11 years, New York Heart Association (NYHA) class I/II/III/IV 9/44/39/8%, median N-terminal pro-B-type natriuretic peptide (NT-proBNP) 878 pg/mL (interquartile range-IQR 348-2480 pg/mL), median left ventricular ejection fraction (LVEF) 31% (IQR 25-37%)]. Mid-regional pro-adrenomedullin levels (median 0.64 nmol/L, IQR 0.49-0.87 nmol/L) increased with NYHA class (P < 0.0001). During 1-year follow-up, 70 patients (14%) died. Increasing MR-proADM was a predictor of poor survival at 12 months (hazard ratio 1.82, 95% confidence interval 1.24-2.66, P = 0.002) after multivariable adjustment. In receiver-operating characteristic curve analysis of 12-month survival, the area under the curve for MR-proADM and NT-proBNP was similar (P = 0.3). Comparison of Cox proportional hazard models using the likelihood ratio chi(2) statistic showed that both NT-proBNP and MR-proADM added prognostic value to a base model of LVEF, age, creatinine, and NYHA class. Adding MR-proADM to the base model had stronger prognostic power than adding NT-proBNP (both P < 0.01). CONCLUSION: Mid-regional pro-adrenomedullin is an independent predictor of mortality in CHF patients, which adds prognostic information to NT-proBNP.
机译:目的:肾上腺髓质素(ADM)是血管舒张肽。尚未对大量患有慢性心力衰竭(CHF)的患者的血浆水平或其前体进行评估。我们试图探索中部地区的proADM(MR-proADM)。方法和结果:我们评估了501名CHF患者的MR-proADM [年龄63 +/- 11岁,纽约心脏协会(NYHA)I / II / III / IV 9/44/39/8%,中位N末端前B型利钠肽(NT-proBNP)878 pg / mL(四分位间距-IQR 348-2480 pg / mL,左心室射血分数中位数(LVEF)31%(IQR 25-37%)]。 NYHA级患者中区肾上腺髓质素原水平(中位数为0.64 nmol / L,IQR为0.49-0.87 nmol / L)(P <0.0001)。在1年的随访中,有70名患者(14%)死亡。 MR-proADM的增加是多变量调整后12个月生存不良的预测指标(危险比1.82,95%置信区间1.24-2.66,P = 0.002)。在接受者操作的12个月生存特征曲线分析中,MR-proADM和NT-proBNP的曲线下面积相似(P = 0.3)。使用似然比chi(2)统计量比较Cox比例风险模型表明,NT-proBNP和MR-proADM都为LVEF,年龄,肌酐和NYHA类的基础模型增加了预后价值。与基本模型相比,在基本模型中添加MR-proADM的预后要强(均P <0.01)。结论:中部肾上腺髓质素原是CHF患者死亡率的独立预测因子,为NT-proBNP增加了预后信息。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号